Covis Group: AMAG Pharmaceuticals acquisition
Covis Group has agreed to purchase AMAG Pharmaceuticals for approximately $647m on an enterprise basis. AMAG is a commercial-stage development firm focusing on therapies for patients with as-yet unmet needs.
Commenting on the transaction, Covis CEO Michael Porter said, “AMAG’s category leading treatments are strong strategic complements to our existing therapeutic portfolio. Through this combination, we believe we will be able to unlock value for all of our stakeholders, employees and patients through the effective and efficient management of these products, coupled with our two companies’ longstanding commitment to expanding patient access to therapy and putting patient interests first.”